excalibur
Diamond Member
- Mar 19, 2015
- 18,109
- 34,294
- 2,290
And naturally, Fauci pushes it in spite of the studies showing its ineffectiveness and dangers.
Is there anything produced or approved by our government for COVID that isn't ineffective, doesn't have terrible side effects, and doesn't actually make the virus worse? The lockdowns, masks, and shots not only failed to work, but caused terrible collateral damage, failed to stop the virus, and, in fact, likely made the virus become more virulent. Now there are reports that remdesivir, which we already know doesn't work and causes renal and liver failure, might also be making the virus itself worse.
Antiviral agents, whether vaccine or therapeutic, must be perfect. If they fail to fully work, they can create viral immune escape, whereby the virus learns how to mutate around them. It's sort of like the principle of shooting at the king and missing, a principle we are often concerned with regarding the overuse or misuse of antibiotics.
Researchers from the Yale School of Medicine posted a preprint study in which they discovered a mutated version of SARS-CoV-2 that appears to have redeveloped in a previously infected immunocompromised woman who was treated with remdesivir. Researchers were able to sequence the genome in a way that made it clear it was related to the remdesivir use in the patient. The patient was later cured by monoclonal antibodies. "This case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with SARS-CoV-2 infection," the study's authors wrote.
...
But it gets worse. On Dec. 12, 2019, less than five months before Fauci and the FDA pushed approval of remdesivir without consulting with an outside panel of experts, the New England Journal of Medicine published a study on remdesivir use in Ebola that should have gotten the drug permanently banned for any use. Over the preceding year, the researchers conducted a randomized controlled trial of four therapeutics for use against Ebola in the Democratic Republic of Congo: remdesivir and three types of monoclonal antibodies, including Regeneron. What were the results in Table 2 of the study?
Of the four drugs, remdesivir had the worst outcome with a 53.1% death rate, which is higher than the death rate from the virus. In fact, both remdesivir and ZMapp (death rate of 49.7%) were deemed to be so dangerous that they were pulled from the study on Aug. 9, 2019. Incidentally, Regeneron, which had the lowest death rate, is the monoclonal antibody therapy that seems to work well for COVID. Why would Fauci first pick remdesivir over Regeneron?
On April 29, Fauci announced that remdesivir would become the standard of care, and another study he cited was Gilead's own March 2020 study (eventually published in the NEJM in June) of 53 coronavirus patients in the U.S. Canada, Europe, and Japan who used remdesivir for 10 days. Sixty percent reported adverse events and 23% reported serious adverse events, the most common being "multiple-organ-dysfunction syndrome, septic shock, acute kidney injury, and hypotension." Furthermore, "Four patients (8%) discontinued remdesivir treatment prematurely: one because of worsening of preexisting renal failure, one because of multiple organ failure, and two because of elevated aminotransferases, including one patient with a maculopapular rash."
This is why the NIH to this day warns about renal failure and liver toxicity from the use of this drug that is bankrupting us and killing people in the hospitals. The WHO recommends against using it. The WHO's Solidarity trial, which was conducted on 2,750 patients in 405 hospitals across 30 countries, found "little or no effect of remdesivir on mortality," even though "the proportion of lower-risk patients happened to be appreciably greater in the remdesivir group than in the placebo group."
Last year, in France's Bichat-Claude Bernard University Hospital, researchers studied outcomes in the first five COVID ICU patients who were administered remdesivir. Researchers observed, "Remdesivir was interrupted before the initially planned duration in four patients, two because of alanine aminotransferase elevations (3 to 5 normal range) and two because of renal failure requiring renal replacement." Elevated alanine aminotransferase is usually an indication of liver toxicity, one of the warnings the NIH has given about the use of remdesivir.
...
www.theblaze.com
Is there anything produced or approved by our government for COVID that isn't ineffective, doesn't have terrible side effects, and doesn't actually make the virus worse? The lockdowns, masks, and shots not only failed to work, but caused terrible collateral damage, failed to stop the virus, and, in fact, likely made the virus become more virulent. Now there are reports that remdesivir, which we already know doesn't work and causes renal and liver failure, might also be making the virus itself worse.
Antiviral agents, whether vaccine or therapeutic, must be perfect. If they fail to fully work, they can create viral immune escape, whereby the virus learns how to mutate around them. It's sort of like the principle of shooting at the king and missing, a principle we are often concerned with regarding the overuse or misuse of antibiotics.
Researchers from the Yale School of Medicine posted a preprint study in which they discovered a mutated version of SARS-CoV-2 that appears to have redeveloped in a previously infected immunocompromised woman who was treated with remdesivir. Researchers were able to sequence the genome in a way that made it clear it was related to the remdesivir use in the patient. The patient was later cured by monoclonal antibodies. "This case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with SARS-CoV-2 infection," the study's authors wrote.
...
But it gets worse. On Dec. 12, 2019, less than five months before Fauci and the FDA pushed approval of remdesivir without consulting with an outside panel of experts, the New England Journal of Medicine published a study on remdesivir use in Ebola that should have gotten the drug permanently banned for any use. Over the preceding year, the researchers conducted a randomized controlled trial of four therapeutics for use against Ebola in the Democratic Republic of Congo: remdesivir and three types of monoclonal antibodies, including Regeneron. What were the results in Table 2 of the study?
Of the four drugs, remdesivir had the worst outcome with a 53.1% death rate, which is higher than the death rate from the virus. In fact, both remdesivir and ZMapp (death rate of 49.7%) were deemed to be so dangerous that they were pulled from the study on Aug. 9, 2019. Incidentally, Regeneron, which had the lowest death rate, is the monoclonal antibody therapy that seems to work well for COVID. Why would Fauci first pick remdesivir over Regeneron?
On April 29, Fauci announced that remdesivir would become the standard of care, and another study he cited was Gilead's own March 2020 study (eventually published in the NEJM in June) of 53 coronavirus patients in the U.S. Canada, Europe, and Japan who used remdesivir for 10 days. Sixty percent reported adverse events and 23% reported serious adverse events, the most common being "multiple-organ-dysfunction syndrome, septic shock, acute kidney injury, and hypotension." Furthermore, "Four patients (8%) discontinued remdesivir treatment prematurely: one because of worsening of preexisting renal failure, one because of multiple organ failure, and two because of elevated aminotransferases, including one patient with a maculopapular rash."
This is why the NIH to this day warns about renal failure and liver toxicity from the use of this drug that is bankrupting us and killing people in the hospitals. The WHO recommends against using it. The WHO's Solidarity trial, which was conducted on 2,750 patients in 405 hospitals across 30 countries, found "little or no effect of remdesivir on mortality," even though "the proportion of lower-risk patients happened to be appreciably greater in the remdesivir group than in the placebo group."
Last year, in France's Bichat-Claude Bernard University Hospital, researchers studied outcomes in the first five COVID ICU patients who were administered remdesivir. Researchers observed, "Remdesivir was interrupted before the initially planned duration in four patients, two because of alanine aminotransferase elevations (3 to 5 normal range) and two because of renal failure requiring renal replacement." Elevated alanine aminotransferase is usually an indication of liver toxicity, one of the warnings the NIH has given about the use of remdesivir.
...
Horowitz: Remdesivir is the greatest scandal of the pandemic | Blaze Media
Is there anything produced or approved by our government for COVID that isn't ineffective, doesn't have terrible side effects, and doesn't actually make the virus worse? The lockdowns, masks, and shots not only failed to work, but caused terrible collateral damage, failed to stop the virus, and...
www.theblaze.com
